BMC Cancer

Table 1 Correlations between ESR1 PvuII polymorphisms and clinicopathological features

From: ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer

Characteristics	*ESR1* PvuII Polymorphism		P-value
Characteristics	TT genotype (n = 44)	TC + CC genotype (n = 60)	P-value
Age at biopsy
Mean (+ SD)	47,5 (9,5)	48,1 (10,9)	0,779^b
Median (range)	48,5 (28–68)	47 (22–75)	0,779^b
Grade
Low	19 (36,5)	33 (63,5)	0,234^a
High	25 (48,1)	27 (51,9)	0,234^a
Hormonal Receptor
Negative	9 (34,6)	17 (65,4)	0,359^a
Positive	35 (44,9)	43 (55,1)	0,359^a
ER (Estrogen Receptor)
Negative	13 (40,6)	19 (59,4)	0,817^a
Positive	31 (43,1)	41(56,9)	0,817^a
PR (Progesteron Receptor)
Negative	13 (41,9)	18 (58,1)	0,96^a
Positive	31 (42,5)	42 (57,5)	0,96^a
Her2 status
Negative	33 (44,6)	41 (55,4)	0,458^a
Positive	11 (36,7)	19 (63,3)	0,458^a
Histology
Ductal	41 (43,6)	53 (56,4)	0,407^a
Lobular	3 (30,0)	7 (70,0)	0,407^a
Therapy
Primary hormonal therapy	24 (54,5)	29 (48,3)	0,531^a
Primary chemotherapy	20 (45,5)	31 (51,7)	0,531^a

P value: ^a = Pearson Chi Square; ^b = Independent sample T test

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com